Drug Profile
Research programme: anti-IL-20 antibody - National Cheng Kung University/Novo Nordisk
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator National Cheng Kung University
- Developer National Cheng Kung University; Novo Nordisk
- Class Antibodies
- Mechanism of Action Interleukin 20 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoporosis; Rheumatoid arthritis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Osteoporosis in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Osteoporosis in Taiwan (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Rheumatoid-arthritis in Denmark (Parenteral)